CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 88 filers reported holding CONCERT PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $3,453,660 | -46.8% | 591,380 | -39.0% | 0.00% | -100.0% |
Q3 2022 | $6,495,000 | +116.6% | 969,417 | +36.1% | 0.00% | – |
Q2 2022 | $2,999,000 | +1209.6% | 712,209 | +945.7% | 0.00% | – |
Q1 2022 | $229,000 | -73.9% | 68,107 | -75.6% | 0.00% | – |
Q4 2021 | $878,000 | +34.9% | 278,736 | +40.2% | 0.00% | – |
Q3 2021 | $651,000 | -54.0% | 198,871 | -40.7% | 0.00% | – |
Q2 2021 | $1,414,000 | +536.9% | 335,238 | +653.1% | 0.00% | – |
Q1 2021 | $222,000 | -61.7% | 44,516 | -2.8% | 0.00% | – |
Q4 2020 | $580,000 | +132.0% | 45,818 | +80.0% | 0.00% | – |
Q3 2020 | $250,000 | -7.1% | 25,449 | -5.9% | 0.00% | – |
Q2 2020 | $269,000 | +74.7% | 27,050 | +54.8% | 0.00% | – |
Q1 2020 | $154,000 | -72.9% | 17,479 | -71.7% | 0.00% | – |
Q4 2019 | $569,000 | -45.0% | 61,677 | -64.9% | 0.00% | – |
Q3 2019 | $1,035,000 | +344.2% | 175,866 | +808.7% | 0.00% | – |
Q2 2019 | $233,000 | +49.4% | 19,354 | +49.3% | 0.00% | – |
Q1 2019 | $156,000 | -66.7% | 12,965 | -65.3% | 0.00% | – |
Q4 2018 | $469,000 | -70.3% | 37,399 | -64.8% | 0.00% | – |
Q3 2018 | $1,577,000 | +14.4% | 106,304 | +29.7% | 0.00% | – |
Q2 2018 | $1,379,000 | -33.0% | 81,943 | -8.8% | 0.00% | -100.0% |
Q1 2018 | $2,057,000 | -57.7% | 89,858 | -52.2% | 0.00% | 0.0% |
Q4 2017 | $4,865,000 | +348.4% | 188,033 | +155.6% | 0.00% | – |
Q3 2017 | $1,085,000 | -7.2% | 73,552 | -12.2% | 0.00% | – |
Q2 2017 | $1,169,000 | -25.0% | 83,811 | -8.1% | 0.00% | – |
Q1 2017 | $1,558,000 | -41.9% | 91,236 | -65.0% | 0.00% | – |
Q4 2016 | $2,682,000 | +172.3% | 260,592 | +167.6% | 0.00% | – |
Q3 2016 | $985,000 | -43.0% | 97,365 | -36.7% | 0.00% | -100.0% |
Q2 2016 | $1,728,000 | -53.0% | 153,839 | -42.8% | 0.00% | 0.0% |
Q1 2016 | $3,677,000 | +8.6% | 269,116 | +50.8% | 0.00% | 0.0% |
Q4 2015 | $3,386,000 | -51.3% | 178,502 | -51.8% | 0.00% | -66.7% |
Q3 2015 | $6,949,000 | +5085.8% | 370,226 | +4003.1% | 0.00% | – |
Q2 2015 | $134,000 | -39.1% | 9,023 | -37.9% | 0.00% | – |
Q1 2015 | $220,000 | +411.6% | 14,523 | +351.3% | 0.00% | – |
Q4 2014 | $43,000 | +4.9% | 3,218 | 0.0% | 0.00% | – |
Q3 2014 | $41,000 | -63.1% | 3,218 | -70.6% | 0.00% | – |
Q2 2014 | $111,000 | -87.1% | 10,928 | -82.9% | 0.00% | – |
Q1 2014 | $861,000 | – | 64,053 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 2,610 | $620,000,000 | 6.47% |
Parkman Healthcare Partners LLC | 1,124,072 | $4,732,000 | 1.74% |
Kynam Capital Management, LP | 1,000,000 | $4,210,000 | 1.08% |
EAM Investors, LLC | 850,647 | $3,581,000 | 0.87% |
BVF INC/IL | 3,629,000 | $15,278,000 | 0.74% |
EAM Global Investors LLC | 388,730 | $1,637,000 | 0.40% |
RA Capital Management | 3,307,203 | $13,923,000 | 0.37% |
Nantahala Capital Management | 1,659,840 | $6,988,000 | 0.35% |
AWM Investment Company, Inc. | 504,661 | $2,125,000 | 0.34% |
INGALLS & SNYDER LLC | 1,411,153 | $5,941,000 | 0.31% |